Identification of Low-Abundance Urinary Biomarkers in Lupus Nephritis Using Electrochemiluminescence Immunoassays.
Biomarkers
/ urine
Chemokine CCL17
/ urine
Chemokine CXCL10
/ urine
Diabetic Nephropathies
/ urine
Electrochemical Techniques
/ methods
Enzyme-Linked Immunosorbent Assay
Glomerulosclerosis, Focal Segmental
/ urine
Humans
Immunoassay
/ methods
Interleukin-12 Subunit p40
/ urine
Interleukin-15
/ urine
Interleukin-7
/ urine
Luminescent Measurements
/ methods
Lupus Nephritis
/ diagnosis
Renal Insufficiency, Chronic
/ urine
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
26
02
2018
accepted:
04
12
2018
pubmed:
9
1
2019
medline:
3
1
2020
entrez:
9
1
2019
Statut:
ppublish
Résumé
To investigate the utility of a sensitive platform using electrochemiluminescence (ECL) for the identification of low-abundance urinary protein biomarkers in lupus nephritis (LN). Forty-eight urine samples were obtained from subjects in 2 independent cohorts, each consisting of 3 groups (matched for age, sex, and race) of 8 patients with active LN (renal Systemic Lupus Erythematosus Disease Activity Index [SLEDAI] >0), 8 patients with inactive SLE (renal SLEDAI 0), and 8 healthy controls. Samples were tested using a preexisting 40-plex ECL panel. A custom 5-plex ECL panel was then developed for further validation studies and used to test 140 urine samples (from 44 patients with active LN, 41 patients with inactive SLE, 28 healthy controls, and 27 patients with other kidney diseases). Levels of 17 urinary proteins were elevated (P < 0.05 by 2-tailed Mann-Whitney U test) in samples from patients with active LN compared to samples from patients with inactive SLE and healthy controls in cohort 1, while 9 were similarly elevated in cohort 2. Of these, interleukin-7 (IL-7), IL-12p40, IL-15, interferon-γ-inducible protein 10 (IP-10), and thymus and activation-regulated chemokine (TARC) were chosen for further validation. These 5 proteins were undetectable by enzyme-linked immunosorbent assay (ELISA). Hence, a custom 5-plex ECL panel was developed and used to validate the results from the initial 40-plex screening panel. Urinary IL-7, IL-12p40, IL-15, IP-10, and TARC levels were again significantly elevated in patients with active LN compared to those with inactive SLE and healthy controls, and correlated well with the renal SLEDAI and physician's global assessment of disease activity (R > 0.67, P < 0.05). All 5 urinary proteins were more frequently elevated in LN compared to controls with other chronic kidney diseases, although overall group differences attained significance only for urinary IL-7 and IL-15. Urinary levels of IL-7, IL-12p40, IL-15, IP-10, and TARC are potentially useful diagnostic tools in LN. The use of ECL assays may allow detection of urinary biomarkers that are below ELISA detection limits.
Substances chimiques
Biomarkers
0
CCL17 protein, human
0
CXCL10 protein, human
0
Chemokine CCL17
0
Chemokine CXCL10
0
IL15 protein, human
0
IL7 protein, human
0
Interleukin-12 Subunit p40
0
Interleukin-15
0
Interleukin-7
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
744-755Subventions
Organisme : Alliance for Lupus Research
ID : None
Pays : International
Informations de copyright
© 2019, American College of Rheumatology.